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Letter to the EditorPGC-1 Coactivators and the
Regulation of Skeletal Muscle
Fiber-Type DeterminationDear Editor,
We would like to offer a comment and
alternative viewpoint regarding the recent
manuscript by Zechner et al. (Zechner
et al., 2010), which described the pheno-
typic outcome in skeletal muscle resulting
from genetic loss of function for both
PGC-1a and PGC-1b. Zechner and
coworkers specifically ablated PGC-1b
in skeletal muscle, either alone or in
a global PGC-1a knockout (KO) back-
ground. Based on the findings from these
experiments, Zechner and colleagues
concluded that the PGC-1 coactivators
are dispensable for muscle fiber-type
determination and are not involved in the
development of insulin resistance. While
we have no issues at all with their data,
we think that this conclusion may not be
justified, based on the limitations of the
experimental system and in light of previ-
ously published work.
We have previously demonstrated that
mice with a global PGC-1a KO do not
exhibit a change in the fiber-type distribu-
tion in skeletal muscle (Arany et al., 2005),
exactly as Zechner et al. did in the present
manuscript; however, in contrast, skeletal
muscle-specific KO animals for PGC-1a
have a significant shift from oxidative
toward glycolytic muscle fibers (Hand-
schin et al., 2007). We have noted this
discrepancy between the global and
muscle-selective KOs and have specu-
lated that it most likely originates from
the very complex phenotype of the globalKO mice (Lin et al., 2004). For example, in
addition to the difference in fiber-type
distribution, global PGC-1a KO animals
have a constitutively activated AMPK in
muscle and exhibit a different response
to endurance exercise training, compared
to mice with a muscle-specific ablation
of PGC-1a (Chinsomboon et al., 2009;
Lin et al., 2004). Similar discrepancies be-
tween global and tissue-specific PGC-1a
ablation have been observed in other
organs, including the regulation of hepatic
gluconeogenesis. Therefore, in the exper-
imental context of a global PGC-1a KO
background, any conclusions about the
role of PGC-1a in skeletal muscle fiber-
type regulation could be problematic
and are likely to be confounded.
Of course, other observations, such as
the unchanged insulin sensitivity in the
single and double KO mouse seen by
Kelly’s group, could also be affected by
the previously reported major metabolic
differences in whole-body PGC-1a KOs
versus controls. The whole-body KOs
are characterized by elevated metabolic
rates and hyperactivity, in contrast to the
hypoactivity observed in the PGC-1a
muscle-specific KO mice. The latter also
have altered pancreatic b cell function,
which is not seen in that from the full-
body KOs. Finally, and perhaps most
importantly, both PGC-1a and PGC-1b
expression levels are reduced specifically
in the skeletal muscle of type 2 diabetic
patients. Thus, there are ample publishedCell Metabolismdata to indicate that caution should be
exercised in drawing conclusions from
mice with a full-body KO for PGC-1a to
model the human patients. Conclusive
studies about the physiological function
and pathophysiological dysregulation of
the two PGC-1 coactivators, PGC-1a
and PGC-1b, in skeletal muscle will
have to be performed in tissue-specific
models.
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